SEC-sourced researchBeta

TVTX

Travere Therapeutics, Inc.

US markets

Data passport

CIK: 0001438533
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 21, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

TVTX · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	145,238,000.0000	Feb 19, 2026
December 2024	233,175,000.0000	Feb 19, 2026
December 2025	490,728,000.0000	Feb 19, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	490,728,000.0000	-25,546,000.0000	37,784,000.0000	605,191,000.0000	490,363,000.0000	Feb 19, 2026
December 2024	233,175,000.0000	-321,545,000.0000	-237,475,000.0000	594,125,000.0000	535,048,000.0000	Feb 19, 2026
December 2023	145,238,000.0000	-111,399,000.0000	-280,021,000.0000	—	—	Feb 19, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$490.73M	December 2025	Feb 19, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$233.18M	December 2024	Feb 19, 2026	10-K
Net incomeNetIncomeLoss	-$25.55M	December 2025	Feb 19, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$37.78M	December 2025	Feb 19, 2026	10-K
Total assetsAssets	$605.19M	December 2025	Feb 19, 2026	10-K
Total liabilitiesLiabilities	$490.36M	December 2025	Feb 19, 2026	10-K

New filings

Explore methodology ↗